Skip to main content
SpringerLink
Log in

Cochrane Rapid Reviews: Immun-Checkpoint-Inhibitor Pembrolizumab vs. Chemotherapie zur Behandlung von fortgeschrittenen Urothelkarzinomen

Cochrane Rapid Review: the immune checkpoint inhibitor pembrolizumab versus chemotherapy for the treatment of advanced urothelial carcinoma

  • Evidenzbasierte Medizin
  • Published:
Der Urologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Bedke J, Stühler V, Todenhöfer T, Stenzl A (2018) Mode of action, new targets and potential biomarkers in modern immunotherapy. Urologe A 57(11):1301–1308

    Article  CAS  Google Scholar 

  2. Bellmunt J, deWit R, Vaughn DJ, Fradet Y, Lee J‑L, Fong L et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015–1026

    Article  CAS  Google Scholar 

  3. Ganann R, Ciliska D, Thomas H (2010) Expediting systematic reviews: methods and implications of rapid reviews. Implement Sci 19(5):56

    Article  Google Scholar 

  4. Loidl W, Luger F (2018) Immunotherapy for locally advanced and metastasized bladder cancer. Urologe A 57(11):1334–1341

    Article  CAS  Google Scholar 

  5. Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM, Witjes JA (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 56(2):247–256

    Article  Google Scholar 

  6. Nussbaumer-Streit B, Klerings I, Wagner G, Heise TL, Dobrescu AI, Armijo-Olivo S, Stratil JM, Persad E, Lhachimi SK, Van Noord MG, Mittermayr T, Zeeb H, Hemkens L, Gartlehner G (2018) Abbreviated literature searches were viable alternatives to comprehensive searches: a meta-epidemiological study. J Clin Epidemiol 102:1–11

    Article  Google Scholar 

  7. Pang T, Amul HGG (2018) Rapid guidelines—timely and important guidance needed for setting standards and best practices. Health Res Policy Syst 16:56

    Article  Google Scholar 

  8. Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM, Castellano D, Bamias A, Fléchon A, Gravis G, Hussain S, Takano T, Leng N, Kadel EE 3rd, Banchereau R, Hegde PS, Mariathasan S, Cui N, Shen X, Derleth CL, Green MC, Ravaud A (2018) Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391(10122):748–757

    Article  CAS  Google Scholar 

  9. Saluja M, Gilling P (2018) Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: a review. Int J Urol 25(1):18–24

    Article  Google Scholar 

  10. Schünemann HJ, Moja L (2015) Reviews: rapid! Rapid! Rapid! … and systematic. Syst Rev 4:4

    Article  Google Scholar 

  11. Shang PF, Kwong J, Wang ZP, Tian J, Jiang L, Yang K, Yue ZJ, Tian JQ (2011) Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD006885.pub2

    Article  PubMed  Google Scholar 

  12. Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD (2017) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18(3):312–322

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UroEvidence@Deutsche Gesellschaft für Urologie, Nestorstraße 8/9, 10709, Berlin, Deutschland

    D. Wilborn & S. Schmidt

Authors
  1. D. Wilborn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Schmidt.

Ethics declarations

Interessenkonflikt

D. Wilborn und S. Schmidt geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wilborn, D., Schmidt, S. Cochrane Rapid Reviews: Immun-Checkpoint-Inhibitor Pembrolizumab vs. Chemotherapie zur Behandlung von fortgeschrittenen Urothelkarzinomen. Urologe 58, 45–48 (2019). https://doi.org/10.1007/s00120-018-0838-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-018-0838-5

Search

Navigation